Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H26FNO4.ClH |
| Molecular Weight | 375.863 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=C(F)C=C1C[C@@](O)(C2CCOCC2)[C@@H]3CNCCO3
InChI
InChIKey=WJDKGRLMNSHPON-CJRXIRLBSA-N
InChI=1S/C18H26FNO4.ClH/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17;/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3;1H/t17-,18+;/m0./s1
Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.
Originator
Approval Year
Sample Use Guides
Open-label study of edivoxetine once daily dosing (0.1-0.3 mg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years.
The efficacy, tolerability, and safety of edivoxetine were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose edivoxetine 6-18 mg once daily with placebo for 10 weeks acute therapy followed by 1 year edivoxetine treatment
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CP012282EU
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
C171707
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
1194374-05-4
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
UU-109
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
100000127591
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
DBSALT001261
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
56841862
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
DTXSID50152462
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103857
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY | |||
|
SUB33636
Created by
admin on Mon Mar 31 19:27:12 GMT 2025 , Edited by admin on Mon Mar 31 19:27:12 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD